HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. (11th October 2018)

• Record Type: Journal Article
• Authors: Navari, Rudolph M
• Is Part Of: Future oncology. Volume 15:Number 3(2019)
• Page Start: 241
• Page End: 255
• Publication Date: 2018-10-11
• Subjects: aprepitant -- Cinvanti -- HTX-019; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0577
• Languages: English
• ISSNs: 1479-6694

Abstract

Chemotherapy-induced nausea and vomiting (CINV) may occur during the acute (0–24 h) or delayed (25–120 h) phase following chemotherapy administration. The addition of a neurokinin 1 receptor antagonist to antiemetic regimens containing a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone has resulted in improved CINV prophylaxis. Due to numerous adverse events and hypersensitivity reactions associated with fosaprepitant, a commonly used neurokinin 1 receptor antagonist, there remains an unmet need for better-tolerated formulations. HTX-019, the US FDA-approved polysorbate 80- and synthetic surfactant-free aprepitant injectable emulsion, is bioequivalent to and better tolerated (fewer treatment-emergent adverse events) than fosaprepitant. HTX-019 represents a valuable alternative to fosaprepitant for CINV prophylaxis.